All In Biotech

Drug Trial Radar · NCT05981846

A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19

A Phase II, Randomized, Double-blind, Multi-centre Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 279 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

279

Actual

Start

Sep 4, 2023

Primary completion

Nov 3, 2023

Study completion Nov 3, 2023

Sponsor

Lead sponsor
Hipra Scientific, S.L.UIndustry
Sponsor type
Industry
First posted
Aug 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.

Conditions

  • SARS CoV 2 Infection
  • Influenza, Human

Interventions

  • BIMERVAXBiological

    One dose of booster vaccine

  • SIIVBiological

    One dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination.Time frame: Day 0, Day 7
  2. Number, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through the end of the study.Time frame: Day 0, Day 7, Day 28
  3. Number and percentage of serious adverse events (SAEs) through the end of the study.Time frame: Day 0, Day 7, Day 28
  4. Number and percentage of adverse events of special interest (AESI) through the end of the studyTime frame: Day 0, Day 7, Day 28

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital HM Modelo

    A Coruña, A Coruña, Spain

  • Hospital Clínico Universitario de Santiago

    Santiago de Compostela, A Coruña, Spain

  • Hospital Germans Trias i Pujol

    Badalona, Barcelona, Spain

  • Hospital Clínic de Barcelona

    Barcelona, Barcelona, Spain

  • CAP Centelles

    Centelles, Barcelona, Spain

  • Hospital Josep Trueta

    Girona, Girona, Spain

  • Hospital Regional de Málaga

    Málaga, Málaga, Spain

  • Hospital Clínico de Valladolid

    Valladolid, Valladolid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.